(Q40087324)

17 September 2017

title

Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo (English)

1 reference

17 September 2017

1 reference

1 reference

Dexuan Gao

1

1 reference

17 September 2017

Qinghua Xia

series ordinal

2

1 reference

17 September 2017

Jiaju Lv

series ordinal

3

1 reference

17 September 2017

Hui Zhang

series ordinal

4

1 reference

17 September 2017

publication date

1 September 2007

1 reference

International Journal of Urology

17 September 2017

published in

1 reference

17 September 2017

volume

14

1 reference

17 September 2017

issue

9

1 reference

17 September 2017

page(s)

838-845

1 reference

17 September 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

A transcriptional co-repressor that interacts with nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Coactivator and corepressor complexes in nuclear receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

What's up and down with histone deacetylation and transcription?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

P21Waf1 control of epithelial cell cycle and cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

The patient with hormone-refractory prostate cancer: determining who, when, and how to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase as a new target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Anti-tumor mechanisms of valproate: a novel role for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01823.X

10.1111/J.1442-2042.2007.01823.X

21 January 2018

Identifiers

DOI

1 reference

17 September 2017

1 reference